Physician profile
George Batty
NPI 1003020413
$505.72
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.17 · 2020: $159 · 2023: $168 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $137.62 | 2019-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $45.71 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $42.03 | 2023 | Enhertu |
| Abbvie INC. | $35.52 | 2020-2023 | Venclexta |
| Daiichi Sankyo INC. | $26.37 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $26.32 | 2024 | |
| Deciphera Pharmaceuticals INC. | $23.10 | 2024 | Qinlock |
| Merck Sharp & Dohme LLC | $22.25 | 2023 | Keytruda, Lynparza |
| Tersera Therapeutics LLC | $20.24 | 2024 | Quzyttir |
| Boston Scientific Corporation | $19.82 | 2023 | Ams 800 Artificial Urinary Sphincter |
| Exelixis INC. | $16.85 | 2024 | Cabometyx |
| Pfizer INC. | $16.82 | 2019 | |
| Puma Biotechnology, INC. | $15.00 | 2020 | |
| Amgen INC. | $14.85 | 2020 | |
| Eisai INC. | $14.81 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $14.37 | 2024 | Tivdak |
| Genentech USA, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Batty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.